BeOne Medicines (ONC) Insider Lazelle Buys 18,980 Shares

Sawyers Charles Lazelle made a notable purchase of 18,980 shares of ONC on June 11, 2026. The transaction was executed at a price of $0.0 per share, indicating a non-cash acquisition. This move comes as ONC shares traded at $264.48.

Other Institutional Activity in ONC

Baker Bros. Advisors LP maintained its position in ONC with 8,799,053 shares valued at approximately $2.61 billion. Meanwhile, Primecap Management Co/CA/ slightly reduced its holdings by 5,400 shares, bringing its total to 4,975,181 shares worth about $1.48 billion. Capital International Investors significantly cut its stake by 955,140 shares, ending with 4,158,726 shares valued at $1.23 billion. FMR LLC also reduced its position by 299,017 shares, holding 3,693,610 shares worth $1.10 billion. On the other hand, Citadel Advisors LLC increased its holdings by 516,719 shares, nearly doubling its stake to 1,050,236 shares valued at $306.58 million.

BeOne Medicines AG Stock Down 29.3%

ONC shares recently traded at $264.48. The stock's performance is closely watched by investors, with a 52-week range that has seen significant fluctuations. Major institutional investors hold substantial positions, indicating confidence in the company's potential.

Insider Buying and Selling at BeOne Medicines AG

Several insiders made purchases on June 11, 2026. Shalini Sharp acquired 18,980 shares, Xiaodong Wang bought 193,492 shares, and Chan Henry Lee, the Senior Vice President and General Counsel, purchased 45,071 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On June 2, 2026, RBC Capital maintained its 'buy' rating for ONC, setting a price target of $436. Leerink Partners and Guggenheim also maintained 'buy' ratings, with targets of $367 and $420, respectively. Barclays and Truist Securities echoed similar sentiments with 'buy' ratings and targets of $409 and $413. Wells Fargo initiated coverage with a 'buy' rating and a $400 target, while Wolfe Research started with a $340 target. Jefferies downgraded the stock to 'hold' with a $290 target on March 16, 2026.

Bottom Line

The recent insider purchase by Sawyers Charles Lazelle highlights ongoing interest in ONC. With significant institutional holdings and positive analyst ratings, ONC remains a stock to watch. Investors are reminded that insider purchases can reflect confidence but do not guarantee future performance.